Loading...
Loading...
In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Nanosphere NSPH with a Buy rating, and raised the price target from $3.50 to $5.50.
In the report, Jefferies noted, “Aided by its first mover-advantage status, we expect NSPH's proprietary gram-positive blood stream infection test to drive significant new system placements and revenue growth over the next several years. Assuming coverage at Buy / $5.50 price target.”
Nanosphere closed on Thursday at $3.88.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in